Search Results

Biotech Bay

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

FibroGen, Inc. announced a royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth.

November 7, 2022

·

5 min read

Business

NovaQuest Private Equity Announces Investment In Bend Bioscience to Broaden CoreRx Offering

Bend Bioscience and QHP Capital (“QHP”), the management company for NovaQuest Private Equity (“NQPE”), have announced plans to invest in a new operation in Bend, Oregon , an emerging hub of biotechnology R&D and manufacturing.

October 11, 2022

·

3 min read

Business

Grünenthal and NovaQuest Enter Agreement to Advance the Resiniferatoxin Global Phase III Program in Osteoarthritis

Grünenthal and NovaQuest announced that they have entered an agreement to advance the global clinical Phase III programme of Grünenthal’s asset resiniferatoxin.

March 29, 2022

·

6 min read

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company’s antibody-cleaving enzyme technology platform

Hansa Biopharma AB, (Hansa), (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that the Company has entered into an agreement with U.S.-based NovaQuest Capital Management, securing $70 million in non-dilutive financing.

July 18, 2022

·

5 min read

Bio NC

TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry

TARGAN (formerly Applied LifeSciences & Systems (ALSS)) announced today it has secured $35 million of Series C equity financing.

May 25, 2022

·

7 min read

Business

Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

September 3, 2024

·

3 min read

Deals

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Aceragen, Inc. announced the acquisition of Enzyvant’s RVT-801, an investigational enzyme replacement therapy for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists.

May 3, 2021

·

7 min read

Deals

Catalyst Clinical Research, LLC To Accelerate Growth With The Acquisition By NovaQuest Capital Management, LLC’s Private Equity Group

Catalyst Clinical Research, LLC today announced that the private equity group of NovaQuest Capital Management, LLC

October 31, 2018

·

3 min read

Deals

NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program

Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.

January 3, 2018

·

6 min read

Bio NC

Mycovia Pharmaceuticals, Inc. Announces AllianceRx Walgreens Pharmacy and Walgreens Community-based Specialty Pharmacies as Exclusive Distributor of VIVJOA®

Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that patients now have exclusive access to VIVJOA® through AllianceRx Walgreens Pharmacy and Walgreens community-based specialty pharmacies, subsidiaries of Walgreens Boots Alliance, Inc.

March 26, 2024

·

5 min read